ASTELLAS PHARMA A/S: Financial statements 2026
CVR: 10888638
Source: annual report 2026, Danish Business Authority
01/04/2025 – 31/03/2026
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2026. In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. That is an increase of 3.6% compared with the year before. The profit margin was 2.6%. Equity in the 2026 report amounted to EUR 20,071,000. The solvency ratio was 18.1%.
- Revenue
- EUR 197,863,000
- Gross Profit
- EUR 22,028,000
- Profit/Loss
- EUR 5,229,000
- Equity
- EUR 20,071,000
- Total Assets
- EUR 110,985,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | 197.9M EUR | 22M EUR | 5.2M EUR | 20.1M EUR | 0 |
| 2025 | 191M EUR | 24.4M EUR | 5.7M EUR | 20.8M EUR | 96 |
| 2024 | 186.9M EUR | 20.9M EUR | 4.5M EUR | 24.7M EUR | 97 |
| 2023 | 180.8M EUR | 23.1M EUR | 2.1M EUR | 35.3M EUR | 120 |
| 2022 | 179.9M EUR | 26.2M EUR | 6.7M EUR | 58.2M EUR | 120 |
Official annual report
Find more companies like ASTELLAS PHARMA A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2026
ASTELLAS PHARMA A/S has won the tender "Amgros 2027 1.1491.a" issued by Amgros I/S worth 1,760,850,000 DKK.
Contact info changed: new phone: 43430355 (June 2, 2026).
As of June 1, 2026, Anne Nymand has joined the board of directors of ASTELLAS PHARMA A/S.
As of June 1, 2026, Giuseppe Maduri has joined the board of directors of ASTELLAS PHARMA A/S.
As of May 31, 2026, Malene Abildstrøm has left the board of directors of ASTELLAS PHARMA A/S.
As of May 31, 2026, Rowena Borenstein has left the board of directors of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.472.a" issued by Amgros I/S worth 34,700,000 DKK.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.